SRC and cancer: Through the analysis of cancer cell line pharmacogenomics datasets, we showed that the INT-CDC signature was also predictive of higher sensitivity to tyrosine kinase inhibitors (TKIs), including EGFR, ABL, and IGFR signaling inhibitors, and to SRC and MAPK signaling inhibitors.